NewcelX (NCEL) Accumulated Expenses (2019 - 2025)
NewcelX (NCEL) posted quarterly Accumulated Expenses of $880000.0 for Q4 2025, up 502.74% year-over-year from $146000.0 in Q4 2024, and up 5106.48% quarter-over-quarter from $16902.0 in Q2 2025.
NewcelX (NCEL) Accumulated Expenses (2019 - 2025) Analysis & Trends
NewcelX (NCEL) has reported Accumulated Expenses for 7 consecutive years, with $880000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses rose 502.74% year-over-year to $880000.0; the TTM figure through Dec 2025 stood at $880000.0 (up 502.74% YoY), while the FY2025 annual figure was $880000.0, up 502.74% from the prior year.
- Accumulated Expenses rose to $880000.0 in Q4 2025 per NCEL's latest filing, from $16902.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $986437.0 in Q4 2022 and bottomed at $16902.0 in Q2 2025.
- Historically, Accumulated Expenses has averaged $655367.4 across 5 years, with a median of $737294.5 in 2021.
- On a YoY basis, Accumulated Expenses climbed as much as 502.74% in 2025 and fell as far as 98.1% in 2025.
- NewcelX's Accumulated Expenses stood at $666449.0 in 2021, then jumped by 48.01% to $986437.0 in 2022, then slipped by 2.68% to $960025.0 in 2023, then slumped by 84.79% to $146000.0 in 2024, then surged by 502.74% to $880000.0 in 2025.
- Business Quant data shows NCEL's Accumulated Expenses at $880000.0 in Q4 2025, $16902.0 in Q2 2025, and $146000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | NewcelX | 12.54 Mn | 10.34 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 880,000.00 |
| Jun 30, 2025 | 16,902.00 |
| Dec 31, 2024 | 146,000.00 |
| Jun 30, 2024 | 888,672.00 |
| Dec 31, 2023 | 960,025.00 |
| Jun 30, 2023 | 779,349.00 |
| Dec 31, 2022 | 986,437.00 |
| Jun 30, 2022 | 534,600.00 |
| Dec 31, 2021 | 666,449.00 |
| Jun 30, 2021 | 695,240.00 |
| Dec 31, 2020 | 650,753.00 |
| Dec 31, 2019 | 562,465.00 |